Health · Medical Research · 2 hrs ago
Imagion secures first site for MagSense breast cancer trial
Imagion Biosystems has signed its first US trial site for a study of its MagSense imaging agent in HER2-positive breast cancer.
The site is Regis Clinical Research, an oncology-focused research organisation in Miami.
The Phase 1b/2 trial will assess MagSense as a diagnostic imaging agent for this breast cancer subtype.
MagSense uses targeted magnetic nanoparticles to enhance MRI images without radioactive tracers or ionising radiation.
The study will test safety, dosing and diagnostic performance in three parts, with interim analyses planned after the first two.
Seven other sites have been selected, and Imagion is working to finalise their contracts and activate them.
Recruitment is expected after site activation, and the trial is expected to take 18 to 24 months.
Imagion Biosystems has signed an agreement with Regis Clinical Research, securing the first site for its Phase 1b/2 MagSense trial in HER2-positive breast cancer.
The US-based site is expected to begin patient recruitment shortly after site initiation activities.
Seven further sites have been selected, with contracts and activation still being progressed.
The trial is designed in three parts and is expected to take 18 to 24 months.
MagSense uses targeted magnetic nanoparticles to enhance MRI imaging without radioactive tracers or ionising radiation.
- Who
- Imagion Biosystems and Regis Clinical Research.
- What
- They signed a clinical trial agreement making Regis the first site for Imagion’s Phase 1b/2 MagSense trial in HER2-positive breast cancer.
- When
- The agreement was announced on November 16, 2026. Patient recruitment is expected to start shortly after site initiation activities.
- Where
- Regis Clinical Research is based in Miami, United States.
- Why
- To advance the trial and assess MagSense’s diagnostic performance in HER2-positive breast cancer.
This story does not have two clearly opposing sides.
Imagion announced that it had executed a clinical trial agreement with Regis Clinical Research.
Patient recruitment is expected to start shortly.
The study is planned to proceed through Parts A, B and C, with interim analyses after Parts A and B.
- First trial site
- Regis Clinical Research
- Trial
- Phase 1b/2 MagSense study in HER2-positive breast cancer
- Additional sites selected
- Seven
- Expected trial duration
- 18–24 months
- Trial parts
- Three
- Recruitment
- Expected shortly after site initiation activities
What people are saying
We are excited to have Regis as our first trial site under contract
As an organisation focused on efficient study execution and with deep experience across oncology trials, Regis aligns with IBX’s focus on expediently advancing our clinical development goals.